17.30
2.50%
-0.4235
Travere Therapeutics Inc stock is traded at $17.30, with a volume of 728.24K.
It is down -2.50% in the last 24 hours and down -3.32% over the past month.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
See More
Previous Close:
$17.72
Open:
$17.69
24h Volume:
728.24K
Relative Volume:
0.40
Market Cap:
$1.52B
Revenue:
$203.45M
Net Income/Loss:
$-351.45M
P/E Ratio:
-3.8267
EPS:
-4.52
Net Cash Flow:
$-369.41M
1W Performance:
-9.21%
1M Performance:
-3.32%
6M Performance:
+185.10%
1Y Performance:
+195.34%
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888-969-7879
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
TVTX | 17.30 | 1.52B | 203.45M | -351.45M | -369.41M | -4.52 |
VRTX | 467.14 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 760.26 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 565.93 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 230.62 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.14 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-27-24 | Downgrade | Guggenheim | Buy → Neutral |
Dec-05-23 | Upgrade | Citigroup | Neutral → Buy |
Nov-20-23 | Initiated | Citigroup | Neutral |
Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
Sep-06-23 | Resumed | Evercore ISI | Outperform |
Jul-21-23 | Initiated | JP Morgan | Overweight |
Jun-07-23 | Resumed | Piper Sandler | Neutral |
May-22-23 | Initiated | TD Cowen | Outperform |
May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
Mar-01-23 | Initiated | Guggenheim | Buy |
Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
Dec-14-22 | Initiated | Stifel | Hold |
Dec-05-22 | Initiated | Wells Fargo | Overweight |
Sep-21-22 | Initiated | Bryan Garnier | Sell |
Jul-14-22 | Resumed | Canaccord Genuity | Buy |
Mar-31-22 | Initiated | Piper Sandler | Overweight |
Feb-28-22 | Initiated | H.C. Wainwright | Buy |
May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
Los Angeles Capital Management LLC Sells 56,866 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
When (TVTX) Moves Investors should Listen - Stock Traders Daily
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
ARMISTICE CAPITAL, LLC Acquires Significant Stake in Travere The - GuruFocus.com
Woodline Partners LP Expands Stake in Travere Therapeutics Inc - GuruFocus.com
Deep Track Capital, LP Reduces Stake in Travere Therapeutics Inc - GuruFocus.com
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $22.00 - MarketBeat
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Travere Therapeutics Awards 24,400 RSUs to New Employees in Talent Acquisition Push | TVTX Stock News - StockTitan
Alport Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook Therapeutics - The Globe and Mail
Travere Therapeutics Completes $143.8 Million Public Offering - Marketscreener.com
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares - The Manila Times
3 Under-the-Radar Healthcare Companies - sharewise
3 Under-the-Radar Healthcare Companies to Watch - MarketBeat
Unitedhealth Group Inc (UNH-N) QuotePress Release - The Globe and Mail
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Reaches New 12-Month HighHere's What Happened - MarketBeat
TVTX stock soars to 52-week high, hits $19.29 amid robust gains - Investing.com India
Latham & Watkins Advises on Travere Therapeutics’ Public Offering of Common Stock - Latham & Watkins LLP
Travere Therapeutics plans public stock offering By Investing.com - Investing.com Australia
Travere Therapeutics Announces Pricing of Public Offering of Common Stock - The Manila Times
Travere Therapeutics Announces Pricing of Public Offering of Common Stock - Benzinga
Travere Therapeutics plans public stock offering - Investing.com India
Travere Therapeutics Launches Public Stock Offering, Led by Jefferies & Leerink | TVTX Stock News - StockTitan
Travere Therapeutics' SWOT analysis: filspari approval boosts rare disease stock outlook - Investing.com UK
Vanguard Group Inc's Strategic Acquisition in Travere Therapeuti - GuruFocus.com
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates - MSN
Travere Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Travere Therapeutics, Inc. (NASDAQ:TVTX) Holdings Raised by Emerald Mutual Fund Advisers Trust - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Scotiabank Analyst Says - Defense World
TVTXTravere Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Scotiabank Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
Evercore ISI raises Travere Therapeutics target to $33 By Investing.com - Investing.com Australia
Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call Transcript - Insider Monkey
Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid Operational Challenges - GuruFocus.com
Travere Therapeutics Boosts Sales with FILSPARI Approval - TipRanks
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry - Simply Wall St
Travere: Q3 Earnings Snapshot - The Washington Post
Travere Therapeutics earnings beat by $1.34, revenue topped estimates - Investing.com Australia
Travere Therapeutics Inc Reports Q3 2024 Revenue of $62.9 Millio - GuruFocus.com
Travere Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times
Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Report Preview: What to Expect - GuruFocus.com
TD Cowen reiterates Buy on Travere shares after PARASOL findings By Investing.com - Investing.com Canada
Semanteon Capital Management LP Purchases Shares of 36,699 Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Travere Therapeutics Inc Stock (TVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Travere Therapeutics Inc Stock (TVTX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
LYONS GARY A | Director |
Oct 04 '24 |
Sale |
14.73 |
40,000 |
589,101 |
51,000 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):